XML 35 R12.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Inventories | 12 Months Ended
--- | ---
Dec. 31, 2017
Inventory Disclosure [Abstract] |
Inventories |
5. | Inventories
We began capitalizing inventory during the fourth quarter of 2017 in connection with the FDA’s approval of HEPLISAV-B on November 9, 2017, as the related costs were expected to be recoverable through the commercialization of the product. Prior to the FDA’s approval, costs to manufacture HEPLISAV-B were expensed as research and development expense as incurred, rather than capitalized as inventory as there was no alternative future use. At December 31, 2017, inventory consisted of work in progress of $0.3 million. There was no write down related to excess or expiring inventory during 2017.

X
- References No definition available. + Details
Name: | us-gaap_InventoryDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 330 -URI http://asc.fasb.org/topic&trid=2126998 + Details
Name: | us-gaap_InventoryDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration